IMPACT and COMPACT

COMPACT/IMPACT Studies

IMPACT (Integrated Molecular Profiling in Advanced Cancer Trial) and COMPACT (Community Oncology Molecular Profiling in Advanced Cancer Trial) are two clinical trials being run by the Princess Margaret Cancer Centre that will help advance Personalized Cancer Medicine by basing treatment on the molecular profile of each patient’s tumor.

Launched on March 1, 2012, IMPACT is the first Canadian comprehensive molecular profiling program that seeks to provide doctors with specific cancer gene information so that each patient’s treatment can be tailored to his/her specific form of the disease.

IMPACT is led by an expert team, including Dr. Lillian Siu, Senior Staff Physician in the Division of Medical Oncology and Hematology, Dr. Phil Bedard, Medical Oncologist and Dr. Suzanne Kamel-Reid, Director of Molecular Diagnostics.

COMPACT is the next stage in the evolution of Personalized Cancer Medicine – taking the model out to community partners beyond The Princess Margaret. Like IMPACT, COMPACT will focus on breast, colorectal, ovarian and non-small cell lung cancer, but will involve 500 patients per year being treated at other centres within a 200km radius, including:

St. Michael’s Hospital
Mount Sinai Hospital
Credit Valley Hospital
Durham Regional Cancer Centre
St. Joseph’s Hospital
William Osler Health Centre
Trillium Health Centre
Royal Victoria Hospital
Grand River Regional Hospital
Sunnybrook Odette Cancer Centre
North York General Hospital
Southlake Regional Health Centre
Markham Stouffville Hospital
Toronto East General Hospital

Patients will be referred to COMPACT by their oncologists and come to The Princess Margaret for testing and to consent to the trial. A report (along with suggested treatment options) will be sent back to their primary physician to be reviewed with the patient. Treatment may take place elsewhere.

This will help us create a Personalized Cancer Medicine network that will benefit patients beyond The Princess Margaret!

Through the IMPACT and COMPACT studies, over 2,000 tumors have been sequenced.